Moderna (MRNA) is not aware of any significant intellectual property impediments for any products it intends to commercialize, including mRNA-1273

Moderna (MRNA) Initiates Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)

Moderna, Inc., (NASDAQ: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Phase 3 study of its mRNA vaccine candidate (mRNA-1273) against COVID-19 has begun dosing participants. The Phase 3 study, called the COVE (Coronavirus Efficacy) study, is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant... More

Moderna (MRNA) Reports $472M Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19

Moderna, Inc. (NASDAQ: MRNA) today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3 study of the Companys mRNA vaccine candidate (mRNA-1273) against COVID-19.

An earlier award from BARDA for up to $483 million was entered into to support the scale up of mRNA-1273 and clinical development, originally with a smaller anticipated number of participants in the Phase 3 clinical trial. Following discussions with the U.S. Food and Drug... More

Arbutus Biopharma (ABUS) Surges on Moderna (MRNA) Patent Win

Arbutus Biopharma (NASDAQ: ABUS) surges after winning IPR patent challenge over Moderna (NASDAQ: MRNA). Shares last up 56%.

Moderna (MRNA) Loses Challenge to Arbutus Patent for Gene Therapy Tech - Bloomberg

Moderna (NASDAQ: MRNA) Loses Challenge to Arbutus (NASDAQ: ABUS) Patent for Gene Therapy Tech - Bloomberg